Insulet (PODD) Stock Price, News & Analysis

-2.48 (-1.32%)
(As of 11:39 AM ET)
Today's Range
50-Day Range
52-Week Range
121,415 shs
Average Volume
904,054 shs
Market Capitalization
$12.94 billion
P/E Ratio
Dividend Yield
Price Target

Insulet MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.82 Rating Score
29.0% Upside
$239.44 Price Target
Short Interest
4.20% of Shares Sold Short
Dividend Strength
Upright™ Environmental Score
News Sentiment
0.20mentions of Insulet in the last 14 days
Based on 19 Articles This Week
Insider Trading
Selling Shares
$1.89 M Sold Last Quarter
Proj. Earnings Growth
From $3.11 to $3.76 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.94 out of 5 stars

Medical Sector

19th out of 918 stocks

Surgical & Medical Instruments Industry

2nd out of 100 stocks

PODD stock logo

About Insulet Stock (NASDAQ:PODD)

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, the Middle East, Australia, and internationally. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.

PODD Stock Price History

PODD Stock News Headlines

Barclays Cuts Insulet (NASDAQ:PODD) Price Target to $200.00
Insulet (PODD) Gets a Hold from Stifel Nicolaus
Insulet (NASDAQ:PODD) PT Raised to $234.00
See More Headlines
Receive PODD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Insulet and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Industry, Sector and Symbol

Surgical & medical instruments
Health Care Equipment
Current Symbol
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Moderate Buy
Rating Score (0-4)
Research Coverage
17 Analysts


Net Income
$206.30 million
Pretax Margin


Sales & Book Value

Annual Sales
$1.70 billion
Cash Flow
$3.76 per share
Book Value
$10.49 per share


Free Float
Market Cap
$13.00 billion

Social Links

Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

PODD Stock Analysis - Frequently Asked Questions

Should I buy or sell Insulet stock right now?

17 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Insulet in the last twelve months. There are currently 3 hold ratings and 14 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" PODD shares.
View PODD analyst ratings
or view top-rated stocks.

What is Insulet's stock price target for 2024?

17 Wall Street analysts have issued 1 year target prices for Insulet's shares. Their PODD share price targets range from $184.00 to $330.00. On average, they anticipate the company's share price to reach $239.44 in the next twelve months. This suggests a possible upside of 29.0% from the stock's current price.
View analysts price targets for PODD
or view top-rated stocks among Wall Street analysts.

How have PODD shares performed in 2024?

Insulet's stock was trading at $216.98 at the start of the year. Since then, PODD stock has decreased by 14.4% and is now trading at $185.66.
View the best growth stocks for 2024 here

When is Insulet's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 13th 2024.
View our PODD earnings forecast

How were Insulet's earnings last quarter?

Insulet Co. (NASDAQ:PODD) released its quarterly earnings data on Thursday, May, 9th. The medical instruments supplier reported $0.73 earnings per share for the quarter, topping the consensus estimate of $0.39 by $0.34. The medical instruments supplier earned $441.70 million during the quarter, compared to analyst estimates of $424.05 million. Insulet had a net margin of 13.14% and a trailing twelve-month return on equity of 34.06%. The business's revenue was up 23.3% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.23 earnings per share.

What guidance has Insulet issued on next quarter's earnings?

Insulet updated its second quarter 2024 earnings guidance on Thursday, May, 9th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $456.0 million-$467.9 million, compared to the consensus revenue estimate of $457.8 million.

What is Shacey Petrovic's approval rating as Insulet's CEO?

61 employees have rated Insulet Chief Executive Officer Shacey Petrovic on Shacey Petrovic has an approval rating of 55% among the company's employees. This puts Shacey Petrovic in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Insulet own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Insulet investors own include NVIDIA (NVDA), DexCom (DXCM), Netflix (NFLX), Alibaba Group (BABA), Tesla (TSLA), Block (SQ), Walt Disney (DIS), Salesforce (CRM), Roku (ROKU) and Trade Desk (TTD).

Who are Insulet's major shareholders?

Insulet's stock is owned by many different institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (11.71%), Capital Research Global Investors (10.80%), Baillie Gifford & Co. (2.06%), Clearbridge Investments LLC (1.81%), William Blair Investment Management LLC (1.36%) and Westfield Capital Management Co. LP (0.67%). Insiders that own company stock include Bret Christensen, Charles Alpuche, Dan Manea, James Hollingshead, John A Fallon, Luciana Borio, Michael P Spears, Prem Singh, Sally Crawford, Shacey Petrovic and Wayde D Mcmillan.
View institutional ownership trends

How do I buy shares of Insulet?

Shares of PODD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:PODD) was last updated on 5/20/2024 by Staff

From Our Partners